Jiangsu Hengrui Pharmaceuticals Co., Ltd.

江苏恒瑞医药股份有限公司

01276.HK

Develops, manufactures and commercializes innovative pharmaceutical drugs, focusing on new molecular entity therapies in oncology and other areas with unmet medical needs, in China and globally. Ranked first among Chinese pharma companies in NME drug revenue in 2023 per Frost & Sullivan.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Connected or related major customers / suppliers
• Distribution model
• Pricing policy and price changes
• Particular sales arrangements
• Capacity and utilisation
• Goodwill, intangibles and asset impairment
• Investments and fair-value assets
• Non-recurring gains and losses
• Related-party transactions and balances